Appointments at the MHRA, Daiichi, Eisai and Takeda – People on the move
The UK Medicines and Healthcare products Regulatory Agency(MHRA) has promoted Mark Brise as group manager, inspections, good manufacturing practice (GMP) and good distribution practice (GDP). Brise succeeds Bryan Wright who retired at the end of March.
Before the promotion Birse worked as one of a number of GMP operations managers at the MHRA. Brise has also worked in the pharmaceutical industry for more than 10 years.
John Gargiulo has been named president and CEO of Daiichi Sankyo, Inc (DSI), the US operation of the Japanese pharma. Gargiulo succeeds Joseph Pieroni who is retiring after 14 years leading Daiichi’s US commercial operations.
Before becoming CEO Gargiulo oversaw US marketing, supply chain, managed markets and new product planning. Gargiulo joined Sankyo in 1995 and played a role in advancing DSI from a joint venture with Parke-Davis.
Eisai has appointed Ye Liu as president of its Chinese subsidiary. Liu becomes the first locally-hired president of the subsidiary. Before taking the position Liu was head of pharmaceuticals affairs division at Eisai.
Stuart Dollow has joined Takeda as managing director of its global research and development centre, Europe. Dollow joins from Norgine and has also worked at Roche and GlaxoSmithKline (GSK).
Shionogi Inc, the Chinese company’s US operation, has appointed John Keller as president and CEO. Keller succeeds Sapan Shah who has left the company. Before joining Shionogi Inc in July 2010 Keller worked at SR One, the venture capital unit of GSK.
Andrew Hindman has been named as president and CEO of Tobira Therapeutics. Hindman has previously worked at Nodality, Onyx Pharmaceuticals and Gilead Sciences.
Michael Lodder has been appointed as chief business officer at Pepscan Therapeutics. Lodder joins from Octoplus where he worked as senior manager business development.
